Screener
Cytokinetics CYTK Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 1,208,487 | 916,975 |
| Long-term investments | 538,317 | 335,048 |
| Property and equipment, net | 78,916 | 79,194 |
| Operating lease right-of-use assets | 72,896 | 75,979 |
| Inventories, long-term | 6,529 | — |
| Other assets | 19,406 | 17,341 |
| Total assets | $1,924,551 | $1,424,537 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's operating lease ROU assets?
- Cytokinetics (CYTK) reported operating lease ROU assets of $72.9M in Q2 2026.
- How has Cytokinetics's operating lease ROU assets changed year-over-year?
- Cytokinetics's operating lease ROU assets decreased by 4.2% year-over-year, from $76.12M to $72.9M.
- What is the long-term trend for Cytokinetics's operating lease ROU assets?
- Over 5 years (2020 to 2025), Cytokinetics's operating lease ROU assets has grown at a 91.8% compound annual growth rate (CAGR), from $2.92M to $75.98M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Cytokinetics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude